Form 4: MariMed CFO Receives RSU Grant in Lieu of Cash Bonus
Statement of Changes in Beneficial Ownership
MariMed CFO Mario Pinho was granted 153,125 restricted stock units in lieu of a portion of his 2025 annual cash bonus.
Summary
- CFO Mario Pinho received a grant of 153,125 Restricted Stock Units (RSUs).
- The grant serves as a substitute for a portion of the executive's annual cash bonus for the fiscal year ending December 31, 2025.
- The RSUs convert to common stock on a one-for-one basis.
- The units are subject to a vesting schedule spanning from July 2026 through April 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.
Positives
- Aligns executive compensation with long-term shareholder interests by utilizing equity rather than cash.
- Preserves corporate cash reserves by settling bonus obligations through equity grants.
Negatives
- Results in potential future dilution for existing shareholders upon the vesting and conversion of the RSUs.
Risks
- Market volatility could impact the ultimate value realized by the executive, though the grant itself is fixed at 153,125 units.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing strictly on executive compensation structure.
Management Comments
- The RSUs were granted in lieu of cash payment of a portion of the Reporting Person's annual bonus for the fiscal year ended December 31, 2025.
Industry Context
StockSavvy.ai notes that it is common practice for growth-stage companies, particularly in the cannabis sector, to utilize equity-based compensation to manage cash flow while incentivizing key management personnel.
Comparison to Industry Standards
- The use of equity in lieu of cash bonuses is a standard retention strategy for mid-cap companies to preserve liquidity.
- The vesting schedule of one year is consistent with standard corporate governance practices for executive performance incentives.
Stakeholder Impact
- Shareholders may experience minor dilution upon the vesting of these units.
Next Steps
- Vesting of the first installment of RSUs on July 15, 2026.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year end for which the bonus was earned. |
| 2026-04-15 | Date of the RSU grant transaction. |
| 2026-07-15 | First vesting installment date. |
| 2026-10-15 | Second vesting installment date. |
| 2027-01-15 | Third vesting installment date. |
| 2027-04-15 | Final vesting installment date. |
Keywords
MariMed, MRMD, CFO, Insider Transaction, Equity Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.